Featured
Living with Polycythemia Vera Requires Balance
Germ Control Nov 2, 2026
Germ Control Nov 2, 2026
School Illness Oct 31, 2026
Breast bruises may not always be harmless, as they can sometimes be a sign of...
A UCSF study links autoantibodies to preterm birth risk, identifying antibodies that may trigger early...
The immune cell ratio predicts healthy aging and disease risks, offering insights into personalized health...
Read our latest Germ Control articles.
Living with polycythemia vera requires balance and paying attention to body cues to avoid overexertion.
polycythemia vera treatment path explained: doctors detail first-line therapeutic phlebotomy and medication timing to help...
The FDA approves Jaypirca for previously untreated CLL and SLL without del(17p), showing improved outcomes...
Living with polycythemia vera requires balance and paying attention to body cues to avoid overexertion.
Living with polycythemia vera requires balance and paying attention to body cues to avoid overexertion.
polycythemia vera treatment path explained: doctors detail first-line therapeutic phlebotomy and medication timing to help patients plan care.
New treatments improve breast cancer outlook for patients with hormone receptor-positive breast cancer, offering more ways to control the disease.
A 2024 study in Frontiers in Oncology finds 15-20% endometrial cancer recurrence risk after treatment, varying by patient factors.
Breast bruises may not always be harmless, as they can sometimes be a sign of cancer, requiring medical evaluation if...
Experts explain how patients and care teams can adapt after a myeloma relapse, addressing treatment strategies and managing expectations.
New drugs target root cause of mastocytosis, offering hope for patients with systemic mastocytosis.
Black Americans face double multiple myeloma risk, experts say. Explore the disparity in incidence and treatment challenges.
Patients with polycythemia vera continue experiencing symptoms despite treatment, impacting daily life. Learn why symptoms persist and management strategies.
The FDA approves Jaypirca for previously untreated CLL and SLL without del(17p), showing improved outcomes in a major clinical trial.